These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29913473)

  • 1. Meropenem/vaborbactam (Vabomere) for complicated urinary tract infection.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):103-105. PubMed ID: 29913473
    [No Abstract]   [Full Text] [Related]  

  • 2. Cefepime/enmetazobactam (Exblifep) for complicated urinary tract infections.
    Med Lett Drugs Ther; 2024 Jul; 66(1707):117-118. PubMed ID: 39008106
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
    Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
    JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
    Lee YR; Baker NT
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
    Wu G; Cheon E
    Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection.
    Burgos RM; Biagi MJ; Rodvold KA; Danziger LH
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1007-1021. PubMed ID: 30106599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections.
    McCarthy MW; Walsh TJ
    Drugs Today (Barc); 2017 Oct; 53(10):521-530. PubMed ID: 29286054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
    Tiengrim S; Phiboonbanakit D; Thunyaharn S; Tantisiriwat W; Santiwatanakul S; Susaengrat W; Srisurat N; Malithong A; Srisangchan P; Thamlikitkul V
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
    Albin OR; Patel TS; Kaye KS
    Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
    Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plazomicin (Zemdri) - a new aminoglycoside antibiotic.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):180-182. PubMed ID: 30681656
    [No Abstract]   [Full Text] [Related]  

  • 13. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2015; 59(6):3656-9. PubMed ID: 25845861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): A meta-analysis of randomized controlled trials.
    Zhang Y; Tao LN; Qu XY; Niu JQ; Ding YH; Zhang SX
    Rev Assoc Med Bras (1992); 2018 Mar; 64(3):253-263. PubMed ID: 29641778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eravacycline (Xerava)--an IV tetracycline for complicated intra-abdominal infections.
    Med Lett Drugs Ther; 2019 Apr; 61(1570):61-63. PubMed ID: 31169809
    [No Abstract]   [Full Text] [Related]  

  • 16. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives].
    Yamamoto A; Yamasaki K
    Nihon Ronen Igakkai Zasshi; 2015; 52(2):153-61. PubMed ID: 25994987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
    Peterson J; Kaul S; Khashab M; Fisher A; Kahn JB
    Clin Ther; 2007 Oct; 29(10):2215-21. PubMed ID: 18042477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escherichia coli: development of carbapenem resistance during therapy.
    Hong T; Moland ES; Abdalhamid B; Hanson ND; Wang J; Sloan C; Fabian D; Farajallah A; Levine J; Thomson KS
    Clin Infect Dis; 2005 May; 40(10):e84-6. PubMed ID: 15844056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014.
    Sader HS; Castanheira M; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4355-60. PubMed ID: 27114273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.